ASX Announcement Cleo Diagnostics Ltd ASX:COV Level 2, 480 Collins Street, Melbourne, VIC, 3000 ACN 655 717 169 T +61 3 9614 0600 E [email protected] Directors Chair and Non-Executive Director Adrien Wing Chief Executive Officer and Executive Director Dr Richard Allman Chief Scientific...
Notice Required Under ASX Listing Rule 3.13.1
Filed with ASX · · 1 page · English
Release
Earlier from CLEO Diagnostics
- CLIA Certified Lab selected - Pivotal US Clinical Validation
- CLEO Receives First Batch of Commercial Test Kits
- Change of Director's Interest Notice x 4
- Cleansing Notice
- Application for quotation of securities - COV
Later from CLEO Diagnostics
- Notice of Annual General Meeting/Proxy Form
- Letter to Shareholders
- CLEO Commences Ovarian Cancer Screening Test Development
- Cleo Files Patents for its Ovarian Cancer Screening Test
- CLEO Commences Analytical Validation Ahead of FDA Submission
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics